282 related articles for article (PubMed ID: 31186067)
41. The CCR5 Gene Edited CD34
Karuppusamy KV; Demosthenes JP; Venkatesan V; Christopher AC; Babu P; Azhagiri MK; Jacob A; Ramalingam VV; Rangaraj S; Murugesan MK; Marepally SK; Varghese GM; Srivastava A; Kannangai R; Thangavel S
Front Immunol; 2022; 13():792684. PubMed ID: 35359982
[TBL] [Abstract][Full Text] [Related]
42. Delivering SaCas9 mRNA by lentivirus-like bionanoparticles for transient expression and efficient genome editing.
Lu B; Javidi-Parsijani P; Makani V; Mehraein-Ghomi F; Sarhan WM; Sun D; Yoo KW; Atala ZP; Lyu P; Atala A
Nucleic Acids Res; 2019 May; 47(8):e44. PubMed ID: 30759231
[TBL] [Abstract][Full Text] [Related]
43. Lentivector Knockdown of CCR5 in Hematopoietic Stem and Progenitor Cells Confers Functional and Persistent HIV-1 Resistance in Humanized Mice.
Myburgh R; Ivic S; Pepper MS; Gers-Huber G; Li D; Audigé A; Rochat MA; Jaquet V; Regenass S; Manz MG; Salmon P; Krause KH; Speck RF
J Virol; 2015 Jul; 89(13):6761-72. PubMed ID: 25903342
[TBL] [Abstract][Full Text] [Related]
44. Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy.
Bai J; Rossi J; Akkina R
AIDS Res Hum Retroviruses; 2001 Mar; 17(5):385-99. PubMed ID: 11282007
[TBL] [Abstract][Full Text] [Related]
45. Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements.
Lattanzi A; Meneghini V; Pavani G; Amor F; Ramadier S; Felix T; Antoniani C; Masson C; Alibeu O; Lee C; Porteus MH; Bao G; Amendola M; Mavilio F; Miccio A
Mol Ther; 2019 Jan; 27(1):137-150. PubMed ID: 30424953
[TBL] [Abstract][Full Text] [Related]
46. Cas9-derived peptides presented by MHC Class II that elicit proliferation of CD4
Simhadri VL; Hopkins L; McGill JR; Duke BR; Mukherjee S; Zhang K; Sauna ZE
Nat Commun; 2021 Aug; 12(1):5090. PubMed ID: 34429421
[TBL] [Abstract][Full Text] [Related]
47. Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector.
Walker JE; Chen RX; McGee J; Nacey C; Pollard RB; Abedi M; Bauer G; Nolta JA; Anderson JS
J Virol; 2012 May; 86(10):5719-29. PubMed ID: 22398281
[TBL] [Abstract][Full Text] [Related]
48. Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases.
Wilen CB; Wang J; Tilton JC; Miller JC; Kim KA; Rebar EJ; Sherrill-Mix SA; Patro SC; Secreto AJ; Jordan AP; Lee G; Kahn J; Aye PP; Bunnell BA; Lackner AA; Hoxie JA; Danet-Desnoyers GA; Bushman FD; Riley JL; Gregory PD; June CH; Holmes MC; Doms RW
PLoS Pathog; 2011 Apr; 7(4):e1002020. PubMed ID: 21533216
[TBL] [Abstract][Full Text] [Related]
49. Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection.
Anderson J; Akkina R
Gene Ther; 2007 Sep; 14(17):1287-97. PubMed ID: 17597795
[TBL] [Abstract][Full Text] [Related]
50. Cell-Delivered Entry Inhibitors for HIV-1: CCR5 Downregulation and Blocking Virus/Membrane Fusion in Defending the Host Cell Population.
Symonds G; Bartlett JS; Kiem HP; Tsie M; Breton L
AIDS Patient Care STDS; 2016 Dec; 30(12):545-550. PubMed ID: 27905841
[TBL] [Abstract][Full Text] [Related]
51. Lentivirus pre-packed with Cas9 protein for safer gene editing.
Choi JG; Dang Y; Abraham S; Ma H; Zhang J; Guo H; Cai Y; Mikkelsen JG; Wu H; Shankar P; Manjunath N
Gene Ther; 2016 Jul; 23(7):627-33. PubMed ID: 27052803
[TBL] [Abstract][Full Text] [Related]
52. Killing two birds with one stone: CRISPR/Cas9 CCR5 knockout hematopoietic stem cells transplantation to treat patients with HIV infection and hematological malignancies concurrently.
Au TY; Arudkumar J; Assavarittirong C; Benjamin S
Clin Exp Med; 2023 Dec; 23(8):4163-4175. PubMed ID: 37500934
[TBL] [Abstract][Full Text] [Related]
53. Antiretrovirals to CCR5 CRISPR/Cas9 gene editing - A paradigm shift chasing an HIV cure.
Khan A; Paneerselvam N; Lawson BR
Clin Immunol; 2023 Oct; 255():109741. PubMed ID: 37611838
[TBL] [Abstract][Full Text] [Related]
54. CRISPR-Edited Stem Cell Transplantation for HIV-Related Gene Modification In Vivo: A Systematic Review.
Widjaya MA; Ju JC; Lee SD
Stem Cell Rev Rep; 2022 Jun; 18(5):1743-1755. PubMed ID: 35169967
[TBL] [Abstract][Full Text] [Related]
55. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation.
Gupta RK; Abdul-Jawad S; McCoy LE; Mok HP; Peppa D; Salgado M; Martinez-Picado J; Nijhuis M; Wensing AMJ; Lee H; Grant P; Nastouli E; Lambert J; Pace M; Salasc F; Monit C; Innes AJ; Muir L; Waters L; Frater J; Lever AML; Edwards SG; Gabriel IH; Olavarria E
Nature; 2019 Apr; 568(7751):244-248. PubMed ID: 30836379
[TBL] [Abstract][Full Text] [Related]
56. Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template.
Sather BD; Romano Ibarra GS; Sommer K; Curinga G; Hale M; Khan IF; Singh S; Song Y; Gwiazda K; Sahni J; Jarjour J; Astrakhan A; Wagner TA; Scharenberg AM; Rawlings DJ
Sci Transl Med; 2015 Sep; 7(307):307ra156. PubMed ID: 26424571
[TBL] [Abstract][Full Text] [Related]
57. Expanding CRISPR/Cas9 Genome Editing Capacity in Zebrafish Using SaCas9.
Feng Y; Chen C; Han Y; Chen Z; Lu X; Liang F; Li S; Qin W; Lin S
G3 (Bethesda); 2016 Aug; 6(8):2517-21. PubMed ID: 27317783
[TBL] [Abstract][Full Text] [Related]
58. Genome editing of CCR5 by CRISPR-Cas9 in Mauritian cynomolgus macaque embryos.
Schmidt JK; Strelchenko N; Park MA; Kim YH; Mean KD; Schotzko ML; Kang HJ; Golos TG; Slukvin II
Sci Rep; 2020 Oct; 10(1):18457. PubMed ID: 33116147
[TBL] [Abstract][Full Text] [Related]
59. Reactivation of γ-globin expression using a minicircle DNA system to treat β-thalassemia.
Ma SP; Gao XX; Zhou GQ; Zhang HK; Yang JM; Wang WJ; Song XM; Chen HY; Lu DR
Gene; 2022 Apr; 820():146289. PubMed ID: 35143940
[TBL] [Abstract][Full Text] [Related]
60. Recent developments in CCR5 regulation for HIV cure.
Garg K; Khan AR; Taneja P
Adv Protein Chem Struct Biol; 2021; 126():123-149. PubMed ID: 34090613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
